Inozyme Pharma, Inc.
SEC CIK 1693011 · INZY · last insider filing 2025-07-03
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Hopfner Robert Lorne | Director | filed 2020 - 2025 |
| Bolte Axel | Director · See Remarks | filed 2020 - 2025 |
| Treco Douglas A | Director · CEO & Chairman | filed 2020 - 2025 |
| Sullivan Lynne Marie | Director | filed 2020 - 2025 |
| Harris Erik | Director | filed 2024 - 2024 |
| Diaz Reinaldo M | Director | filed 2020 - 2024 |
| Mathers Edward T | Director | filed 2020 - 2024 |
| Edwards Martin | Director | filed 2020 - 2024 |
| Bhagat Sarah M | Director | filed 2020 - 2024 |
| Pivotal Bioventure Partners Fund I, L.P. | Director | filed 2020 - 2023 |
| Pivotal Bioventure Partners Fund I U.G.P., Ltd | Director | filed 2020 - 2023 |
| Pivotal Bioventure Partners Fund I G.P., L.P. | Director | filed 2020 - 2023 |
| Inozyme Pharma, Inc. | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Subramanian Sanjay | SVP, CFO & Head of BD | filed 2022 - 2025 |
| Winton Matthew | COO | filed 2023 - 2025 |
| Bjarke Henric Bjorn | See Remarks | filed 2020 - 2022 |
| Dipalma Stephen J. | Interim CFO | filed 2021 - 2021 |
| Basso Stephen | Senior Vice President, Finance | filed 2020 - 2021 |
| Jungles Steven J | See Remarks | filed 2020 - 2021 |
| Wenkert Deborah | SVP, CMO | filed 2021 - 2021 |
| Huertas Pedro | See Remarks | filed 2020 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.